Julie Eiseman entered the industry of Commercial Medical Research in 2004 and has grown to employ 1 to 4 people, generating an annual revenue of $50.000 to $99.999. The NAICS classifies this business under the code 541712, which describes it as a Commercial Medical Research. For further clarification, the SIC classifies this business under the code 8731 and described it as a Commercial Medical Research. The business provides service to the B2B market.
To acquire more information, please contact Julie Eiseman by calling (724) 832-7344 during business hours. You can also write to the business’ Single Location at 521 North Main St, Greensburg, Pennsylvania PA 15601. You can also visit the company’s website at . View this business’ social media profiles on Twitter or on Facebbok .
| Company: | Julie Eiseman |
| Representative: | Julie Eiseman |
| Place of Business: | 521 North Main St, Greensburg, PA 15601 |
| Contact Number: | (724) 832-7344 |
| Type of Service: | Commercial Medical Research |
| SIC Number: | 8731 |
| NAICS Number: | 541712 |
| Locality: | Single Location |
| Market Type: | B2B (Business to Business) |
| Began: | 2004 |
| Income/Year: | $50.000 to $99.999 |
| Laborers: | 1 to 4 |
| Share This Company: |
Julie Eiseman is a company operating from Westmoreland, Pennsylvania providing professional Commercial Medical Research and relevant B2B variables. It was founded in 2004 and registered with the SIC code 8731 as Commercial Medical Research, and with the NAICS code 541712 as Commercial Medical Research.
With a current employee count of 1 to 4, Julie Eiseman has gone to report making $50.000 to $99.999 per annum on its journey towards growth. This company invites you to contact its representative Julie Eiseman at (724) 832-7344 for related queries, or to locate its Single Location using the coordinates 40.31044,-79.546856.
The Single Location can also be found at the street address 521 North Main St in Greensburg, Pennsylvania 15601 and can be engaged online through the company website at , the company Twitter , and Facebook page .